Does It Matter How You Lower LDL or How You Raise HDL?
|
|
- Margaret Horton
- 6 years ago
- Views:
Transcription
1 1
2 Does It Matter How You Lower LDL or How You Raise HDL? Thomas P. Bersot, M.D., Ph.D. Gladstone Institute of Cardiovascular Disease UCSF 25 th Annual Advances in Heart disease 12 December 2008 Disclosures: Research and educational grants, consulting and promotional speaking for Abbott, AstraZeneca, Merck, Merck Schering-Plough, Pfizer, GSK 2
3 Does It Matter How Whether You Lower LDL or How You Raise HDL? Thomas P. Bersot, M.D., Ph.D. Gladstone Institute of Cardiovascular Disease UCSF 25 th Annual Advances in Heart disease 12 December 2008 Disclosures: Research and educational grants, consulting and promotional speaking for Abbott, AstraZeneca, Merck, Merck Schering-Plough, Pfizer, GSK 3
4 Prevalence of Abnormal Levels of LDL-C and HDL-C in 8,500 CHD Patients* LDL-C > 130 mg/dl - 58 % HDL-C < 40 mg/dl - 67 % LDL-C < 130mg/dL & - 29 % HDL-C < 40 mg/dl * Distribution of Lipids in 8,500 Men with Coronary Artery Disease. Rubins HB et al., Am J Cardiol 75: (1995) 4
5 5
6 6
7 Hazard Ratios of Future CHD Events in 15,652 Healthy Women (Highest vs. Lowest Quintiles of Each Variable) Ridker, P. M et al. JAMA 2005;294: Copyright restrictions may apply. 7
8 Relating Lipid Changes to CHD Risk Reductions Reduction in Total Cholesterol R 2 =0.55 Reduction in LDL Cholesterol R 2 =0.53 Reduction in Triglyceride R 2 =0.45 Increase in HDL Cholesterol R 2 =0.65 Reduction in Non-HDL C R 2 =0.65 Reduction in TC/HDL C R 2 =0.86 Meta-analysis by A. Alsheik-Ali, HM Abourjally, E Stanek, M McGovern, JT Kuvin, and RH Karas, Tufts-New England Medical Ctr, Boston, Abstract presented at AHA 2004, based on 3,869 CHD events occurring in 44,170 subjects participating in randomized placebo controlled lipid intervention trials-hhs, FATS, HATS, 4S, WOSCOPS, LIPID, AFCAPS/TEXCAPS, VA-HIT, BIP, DAIS, HPS, PROSPER, ALL-HAT-LLT, ASCOT-LLA 8
9 9
10 10
11 11
12 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl mg/dl
13 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl mg/dl =
14 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl mg/dl = =
15 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl mg/dl = =
16 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = mg/dl = =
17 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =
18 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = ! 161 mg/dl = =
19 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =
20 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =
21 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =
22 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =
23 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =
24 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C 161 mg/dl = = mg/dl = =
25 Two CHD Patients, 64 y.o. LDL-C Goal < 70 mg/dl Pt. 1 Pt. 2 Triglycerides Total Chol LDL-C HDL-C TC/HDL-C % LDL-C 161 mg/dl = = /99=76 % 161 mg/dl = = /189=63% 25
26 26
27 Absolute values of LDL-C and HDL-C are less important than their relationship to each other as assessed by ratios Total cholesterol/hdl-c LDL-C/HDL-C Apolipoprotein B / apolipoprotein AI 27
28 Does It Matter How You Lower LDL or How You Raise HDL? LDL getting to goal is important, but how you get there (i.e. which medicines you use) is not. STATIN FIRST (more evidence). HDL raising HDL-C can be dangerous (consider estrogen and the cholesterol ester transfer protein inhibitor, torcetrapib). For every new drug that raises HDL-C a mortality and morbidity outcomes trial will be required to establish efficacy and safety. 28
29 Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?* Meta-analysis of 5 diet, 3 bile acid sequestrant, 1 partial ileal bypass surgery and 10 statin trials. 81,859 subjects 3 or more years of follow-up (most 5 years) Uniform primary outcome: CHD death or nonfatal myocardial infarction * Robinson J et al., J Am Coll Cardiol 46: (2005) 29
30 Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction? * Result: no difference in the relationship of CHD event reduction and LDL-C reduction irrespective of how LDL-C was lowered. Conclusion: statin benefit is almost entirely due to lowering of LDL-C. The putative clinical benefit of the Pleiotropic effects of statins requires further study. * Robinson J et al., J Am Coll Cardiol 46: (2005) 30
31 31
32 Raising HDL-C Niacin - up to 30% Statins, fibrates % Exercise - dose related (HDL-C varied from 47 to 56 mg/dl in healthy men running 0 to 31 miles weekly*) Ethanol up to 20 %; dose dependent Saturated fat restriction lowers HDL-C * Miles run per week and HDL cholesterol levels in healthy, middle-aged men. Arch Int Med 155: (1995) 32
33 33
34 Characteristics of People with Lowest Risk of Heart Attack (Framingham Heart Study) LDL-C= mg/dl BP < 120/80 (no HTN rx)* HDL-C>60 mg/dl* non-diabetic* non-smoker * Not too common in the overweight or obese Wilson et. al. Circ. 97: (1998) 34
35 The Singing Lipidologist 35
36 Scientific Sessions 05 Dallas, Texas Mammas don t let your babies grow up to be couch girls (orchow boys ) (Apologies and thanks to Waylon and Willie) 36
37 Couch girls like restin an takin things easy and such. They never sweat or exercise much. By the time they re fifty with knees and hips creaky, they mostly stay in one place. An when they do travel they drive the ol pickup to Walmart s closest handicapped space. 37
38 Couch girls like restin an takin things easy and such. They never sweat or exercise much. By the time they re fifty with knees and hips creaky, they mostly stay in one place. An when they do travel they drive the ol pickup to Walmart s closest handicapped space. 38
39 Couch girls like restin an takin things easy and such. They never sweat or exercise much. By the time they re fifty with knees and hips creaky, they mostly stay in one place. An when they do travel they drive the ol pickup to Walmart s closest handicapped space. 39
40 Couch girls like restin an takin things easy and such. They never sweat or exercise much. By the time they re fifty with knees and hips creaky, they mostly stay in one place. An when they do travel they drive the ol pickup to Walmart s closest handicapped space. 40
41 Mammas, don t let your babies grow up to be Couch girls. Walkin with em s better than givin em pearls. Mammas, don t let your babies grow up to be Couch girls. Give em a sports bra, sneakers an shorts and tell em about Title IX sports! 41
42 Mammas, don t let your babies grow up to be Couch girls. Walkin with em s better than givin em pearls. Mammas, don t let your babies grow up to be Couch girls. Give em a sports bra, sneakers an shorts and tell em about Title IX sports! 42
43 Mammas, don t let your babies grow up to be Couch girls. Walkin with em s better than givin em pearls. Mammas, don t let your babies grow up to be Couch girls. Give em a sports bra, sneakers an shorts and tell em about Title IX sports! 43
44 Mammas, don t let your babies grow up to be Couch girls. Walkin with em s better than givin em pearls. Mammas, don t let your babies grow up to be Couch girls. Give em a sports bra, sneakers an shorts and tell em about Title IX sports! 44
45 Chow boys ain t easy to feed right and become hard to hold. They d rather eat greasy than live to be old. Lonestar belt buckles on overstretched levis get tighter and tighter each day, til a plaque ruptures and he dies young - to boot hill you ll haul him away! 45
46 Chow boys ain t easy to feed right and become hard to hold. They d rather eat greasy than live to be old. Lonestar belt buckles on overstretched levis get tighter and tighter each day, til a plaque ruptures and he dies young - to boot hill you ll haul him away! 46
47 Chow boys ain t easy to feed right and become hard to hold. They d rather eat greasy than live to be old. Lonestar belt buckles on overstretched levis get tighter and tighter each day, til a plaque ruptures and he dies young - to boot hill you ll haul him away! 47
48 Chow boys ain t easy to feed right and become hard to hold. They d rather eat greasy than live to be old. Lonestar belt buckles on overstretched levis get tighter and tighter each day, til a plaque ruptures and he dies young - to boot hill you ll haul him away! 48
49 Mammas, don t let your babies grow up to be Chow boys, Don t feed im those steaks an burgers an chips- his belly will swell til he can t see his hips! Mammas, don t let your babies grow up to be Chow boys Before he turns fifty he ll turn in his 6- gun- for syringes and vials of ins lun. 49
50 Mammas, don t let your babies grow up to be Chow boys, Don t feed im those steaks an burgers an chips- his belly will swell til he can t see his hips! Mammas, don t let your babies grow up to be Chow boys Before he turns fifty he ll turn in his 6- gun- for syringes and vials of ins lun. 50
51 Mammas, don t let your babies grow up to be Chow boys, Don t feed im those steaks an burgers an chips- his belly will swell til he can t see his hips! Mammas, don t let your babies grow up to be Chow boys! Before he turns fifty he ll turn in his 6- gun- for syringes and vials of ins lun. 51
52 Mammas, don t let your babies grow up to be Chow boys, Don t feed im those steaks an burgers an chips- his belly will swell til he can t see his hips! Mammas, don t let your babies grow up to be Chow boys, Before he turns fifty he ll turn in his 6- gun- for syringes and vials of ins lun. 52
53 Waylon, Johnny and Willie may think my song silly, but only one s alive. Waylon and Johnny, obese diabetics, aren t the ones who survive. Its 73 year old Willie, a karate black belt who s skinny, who ll see his ninth decade arrive. Farm fresh food, a slug of bourbon or two, its what makes him thrive. 53
54 Waylon, Johnny and Willie may think my song silly, but only one s alive. Waylon and Johnny, obese diabetics, aren t the ones who survive. Its 77 year old Willie, a karate black belt who s skinny, who ll see his ninth decade arrive. Farm fresh food, a slug of bourbon or two, its what makes him thrive. 54
55 Waylon, Johnny and Willie may think my song silly, but only one s alive. Waylon and Johnny, obese diabetics, aren t the ones who survive. Its 77 year old Willie, a karate black belt who s skinny, who ll see his ninth decade arrive. Farm fresh food, a slug of bourbon or two, its what makes him thrive. 55
56 Waylon, Johnny and Willie may think my song silly, but only one s alive. Waylon and Johnny, obese diabetics, aren t the ones who survive. Its 77 year old Willie, a karate black belt who s skinny, who ll see his ninth decade arrive. Farm fresh food, a slug of bourbon or two, its what makes him thrive. 56
57 Mammas, don t let your babies grow up an have MI s. Feed em veggies, fruit, chicken an fish, an don t give in to any fast food wish. Mammas, don t let your babies grow up an have MI s, Walk, swim, run with em- whatever it takes, If Dad does it, too, Viagra s a drug he can forsake! 57
58 Mammas, don t let your babies grow up an have MI s Feed em veggies, fruit, chicken an fish, an don t give in to any fast food wish. Mammas, don t let your babies grow up an have MI s, Walk, swim, run with em- whatever it takes, If Dad does it, too, Viagra s a drug he can forsake! 58
59 Mammas, don t let your babies grow up an have MI s Feed em veggies, fruit, chicken an fish, an don t give in to any fast food wish. Mammas, don t let your babies grow up an have MI s, Walk, swim, run with em- whatever it takes, If Dad does it, too, Viagra s a drug he can forsake! 59
60 Mammas, don t let your babies grow up an have MI s Feed em veggies, fruit, chicken an fish, an don t give in to any fast food wish. Mammas, don t let your babies grow up an have MI s, Walk, swim, run with em- whatever it takes, If Dad does it, too, Viagra s a drug he can forsake! 60
61 61
62 62
Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C
Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C Thomas P. Bersot, M.D., Ph.D. Gladstone Institute of Cardiovascular Disease University
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationThe Heart of a Woman. Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine
The Heart of a Woman Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine American Heart Association Women, Heart Disease and Stroke
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationLipid Management: Beyond LDL
Lipid Management: Beyond LDL Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine University of Kentucky Overview Discuss the concept of residual risk Review current evidence-based medicine
More informationRaising high-density lipoprotein cholesterol: where are we now?
European Heart Journal Supplements (23) 5 (Supplement D), D17 D25 Raising high-density lipoprotein cholesterol: where are we now? Baylor College of Medicine, Houston, Texas, U.S.A. KEYWORDS Apolipoprotein;
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationWhen it comes to the FIELD study, what is...is
Future Lipidology ISSN: 1746-0875 (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/tlip19 When it comes to the FIELD study, what is...is James McKenney To cite this article: James McKenney
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationThe Target is LDL, HDL not so much
The Target is LDL, HDL not so much HDL: A riddle wrapped in a mystery inside an enigma Jacques Genest MD Cardiovascular Research Laboratories McGill University Health Center Disclosure J. Genest MD 2013
More informationTreating Lipids for Prevention of CAD in Women: Matching Therapy to Risk
TREATING LIPIDS FOR PREVENTION OF CAD IN WOMEN: MATCHING THERAPY TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationCARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE
CARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE AFTER YOUR LOVED ONE HAS HAD A HEART ATTACK OR STROKE Heart attack and stroke affects the whole family. If your loved one has had a heart attack or
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationThe Pharmacists Role in Lipid Management
The Pharmacists Role in Lipid Management Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant Clinical Assistant Professor, Univ. of Maryland Learning Objectives 1. ENHANCE your understanding
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationCHOLESTEROL CONTENT CREATED BY. Learn more at
CHOLESTEROL CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents what is cholesterol? 4 Whether this is your first visit or a follow-up, asking your doctor these
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationCOURAGE to Leave Diseased Arteries Alone
COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationThe Cardiovascular Institute Mount Sinai School of Medicine, New York
The Cardiovascular Institute Mount Sinai School of Medicine, New York HDL YES HDL NO Juan Jose Badimon, Ph.D Professor of Medicine Director, Atherothrombosis Research Unit The Mount Sinai School of Medicine
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationControversies in Preventative Cardiology
Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence
More informationCardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az
Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationQué factores de riesgo lipídicos debemos controlar? En qué medida?
Qué factores de riesgo lipídicos debemos controlar? En qué medida? Risk category High risk: CHD or CHD risk equivalents (10- year risk >20%) Moderately high risk: two or more risk factors (10-year risk
More informationAIM HIGH for SATURN and stay SHARP; COURAGE (v1.5)
AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5) Jacques Genest MD Cardiovascular Research Laboratory McGill University Health Center Disclosure J. Genest MD 2012 Advisory Board, Speaker s Bureau, Consultant,
More informationDyslipidemia 울산의대서울아산병원심장병원심장내과이철환
Dyslipidemia 울산의대서울아산병원심장병원심장내과이철환 Presentation General LDL cholesterol HDL cholesterol Future Summary A top healthcare priority 사망 / 인구 10 만 Causes of Death Worldwide, 2008 140 120 2008 년 한국인 5 대사망원인
More informationStatin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018
Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018
More informationPrevention of Heart Disease. Giridhar Vedala, MD Cardiovascular Medicine
Prevention of Heart Disease Giridhar Vedala, MD Cardiovascular Medicine What is Heart Disease? Heart : The most hard-working muscle of our body pumps 4-5 liters of blood every minute during rest Supplies
More informationCETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia
CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:
More informationSince the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT
FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT Since the National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines, 3 large
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationThe Metabolic Syndrome
The Metabolic Syndrome Advances in Internal Medicine David D. Waters, MD May 21, 27 UCSF Metabolic Syndrome: Definition abdominal obesity increased waist circumference atherogenic dyslipidemia low HDL-C,
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More information1. Most of your blood cholesterol is produced by: a. your kidneys b. your liver c. your pancreas d. food consumption (Your liver)
I. TEST YOUR KNOWLEDGE OF CHOLESTEROL Choose the correct answer. 1. Most of your blood cholesterol is produced by: a. your kidneys b. your liver c. your pancreas d. food consumption (Your liver) 2. Only
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationHeart Health. Team Member Workbook Session 1 LEARN IDENTIFY ACT. Learn about HTHU Level 3 and the point system
LEARN Learn about HTHU Level 3 and the point system 01 IDENTIFY Identify the major risk factors for cardiovascular disease and how to improve our cardiovascular health 03 02 ACT Begin our Session 1 Goal
More informationESC/EAS Guidelines for the Management of Dyslipidaemias
ESC/EAS Guidelines for the Management of Dyslipidaemias Professor Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC University Hospital Center Zagreb School of Medicine, University of Zagreb, Croatia Declaration
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationShould we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand
Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Presentation outline Strengths & weaknesses of short-term risk approach Strengths &
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationUnderstanding Cholesterol and Triglycerides
MINTO PREVENTION & REHABILITATION CENTRE CENTRE DE PREVENTION ET DE READAPTATION MINTO Understanding Cholesterol and Triglycerides About This Kit Along with cigarette smoking, high blood pressure, physical
More informationA N A C P S P E C I A L R E P O R T. Understanding and Managing Your. Triglycerides
A N A C P S P E C I A L R E P O R T Understanding and Managing Your Triglycerides What are Triglycerides? Triglycerides are one of several types of fat in your body, and the most common of them all. Along
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationOM s Health Corner Cholesterol & Heart Disease!!
Cholesterol & Heart Disease!! We may associate cholesterol with fatty foods, but most of the waxy substance is made by our own bodies. The liver produces 75% of the cholesterol that circulates in our blood.
More informationSafety of Anacetrapib in Patients with or
Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.
More informationWHAT ABOUT AIM-HIGH?
WHAT ABOUT AIM-HIGH? WHERE DID WE GO WRONG--OR DID WE? AIM-HIGH: ATHEROTHROMBOSIS INTERVENTIONS IN METABOLIC SYNDROME WITHLOW HDL/HIGH TRIGLYCERIDES: IMPACT ON GLOBAL HEALTH OUTCOMES. Funded by NHLBI,
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationNormal cholesterol level for men over 50
Normal cholesterol level for men over 50 Understand what your cholesterol levels mean: Total, LDL, for men and 50 mg per dl their respective numbers have to stay over or under a particular level,. 24-4-2017
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk
ARE YOU AT RISK OF A HEART ATTACK OR STROKE? Understand How Controlling Your Cholesterol Reduces Your Risk CONSIDER YOUR HEART HEALTH: REDUCE YOUR CHOLESTEROL Uncontrolled or continuous high cholesterol
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationBiomarkers are NOT useful Surrogates in Lipid Lowering Trials, but they are great Biomarkers!
Biomarkers are NOT useful Surrogates in Lipid Lowering Trials, but they are great Biomarkers! Robert M Califf MD Vice Chancellor for Clinical Research Duke University CHD Mortality Rate Per 1000 Total
More informationSTATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP
STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC Director of Preventative Cardiology CGH Medical Center, Sterling, Illinois
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationThe Clinical Debates
The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More information